BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Presidio Pharmaceuticals, Inc. 

1700 Owens Street
Suite 585
San Francisco  California  94158  U.S.A.
Phone: 415-655-7560 Fax: 415-986-2864


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Presidio Pharmaceuticals, Inc. Announces a High Rate of Virologic Response in an Ongoing Phase 2 Hepatitis C Trial of a New All-Oral Combination of Presidio's PPI-668 With Boehringer Ingelheim Corporation's Faldaprevir and Deleobuvir 11/4/2013 11:23:22 AM
Boehringer Ingelheim Corporation Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals, Inc. Clinical Collaboration 9/10/2013 9:22:33 AM
Boehringer Ingelheim Corporation Forms JV With Presidio Pharmaceuticals, Inc. 3/13/2013 7:05:44 AM
Biocryst Pharmaceuticals (BCRX), Presidio Pharmaceuticals, Inc. Call Off Proposed $101 Million Acquisition 11/30/2012 7:54:26 AM
Biocryst Pharmaceuticals (BCRX) Snags Presidio Pharmaceuticals, Inc. for $101 Million 10/18/2012 6:54:12 AM
Presidio Pharmaceuticals, Inc. Successfully Completes Phase 1 Proof-of-Concept for PPI-668, its Potent HCV NS5A Inhibitor, in Hepatitis C Patients With Genotype-1 Infection 6/26/2012 10:59:10 AM
Presidio Pharmaceuticals, Inc. Announces a New Clinical Candidate, PPI-383, a Novel Pan-Genotypic Non-Nucleoside Polymerase Inhibitor for HCV 4/23/2012 10:23:50 AM
Presidio Pharmaceuticals, Inc. Announces Phase 1a-1b Clinical Results with PPI-668, a Potent Pan-genotypic HCV NS5A Inhibitor 4/18/2012 10:47:29 PM
Presidio Pharmaceuticals, Inc. Reports Progress with Hepatitis C Antiviral Programs 1/9/2012 6:15:48 AM
Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668 11/4/2011 6:40:08 AM
12345